Advantage of endoscopic-ultrasound-fine-needle aspiration associated to Sendai clinical guidelines in detecting the malignant risk in patients with undetermined pancreatic cysts: Long term follow-up

Pietro Gambitta, Paolo Aseni, Paola Fontana, Emilia Bareggi, Edoardo Forti, Alberto Tringali, Francesco Molteni, Maurizio Vertemati

ABSTRACT

Aims: Contradictory information exists on whether different clinical guidelines are effective in detecting the malignant risk in patients with pancreatic cysts. We have retrospectively evaluated the accuracy and the long-term outcome in patients with pancreatic cysts with a diameter ≥ 2 cm when indication for surgery was established by clinical evaluation of their malignant risk according to Sendai Clinical Guidelines associated to endoscopic-ultrasound-fine-needle aspiration. Methods: Patients with pancreatic cysts with a diameter ≥2 cm were evaluated for their potential malignant risk by endoscopic-ultrasound-fine-needle aspiration associated to the clinical evaluation by Sendai Clinical Guidelines. Long-term outcome and comparison in patients survival as well as the accuracy in detecting malignancies were evaluated with the combined clinical and endoscopic evaluation. Results: Two hundred eighteen patients with pancreatic cysts were observed during a 9-year period of the study and 74 of them (33.9%) presenting with a pancreatic cyst ≥ 2 cm were eligible for the study. Fourteen malignant neoplasms (18.9%) were detected. the accuracy in detecting malignancy of combined clinical and endoscopic evaluation was very high (0.99). The five-year survival rates for patients who underwent surgery with benign and malignant pancreatic cysts and for patients in observational follow-up were similar (70% and 85%). The cohort of patients with malignant pancreatic cysts with ductal adenocarcinoma showed a five-year survival rate of 41%. Conclusion: Endoscopic ultrasound fine-needle aspiration associated to Sendai clinical guidelines showed a high accuracy in detecting malignant risk in patients with pancreatic cysts with a diameter ≥ 2 cm. allowing appropriate selection for surgical treatment with satisfactory long-term survival.

Keywords: Diagnostic imaging, Pancreatic cancer, Pancreatic carcinoma, Pancreatic neoplasm, Pancreatic pseudocyst

How to cite this article

INTRODUCTION

With the increasing current use of advanced abdominal images modalities such as cross-sectional imaging modalities by computed tomography (CT) and magnetic resonance imaging (MRI), pancreatic cysts (PCs) are commonly encountered.

As these lesions have become a common finding, the different types of PCs pose a challenging diagnostic dilemma to assess the potential for malignancy within a cyst [1, 2]. Whereas some lesions show benign behaviour, such as serous cystadenomas (SCA) and pancreatic pseudocysts (PPC), others have an unequivocal malignant potential, such as mucinous cystic neoplasm (MCN), main duct (MD) or mixed type (MT) intraductal papillary mucinous neoplasm (MD/MT-IPMN), solid pseudo-papillary neoplasm (SPPN), pancreatic neuroendocrine neoplasm (PNEN) and, to a lesser extent, some branch duct IPMN (BD-IPMN).

Endoscopic-ultrasound-fine-needle aspiration (EUS-FNA), allows for analysis of the cyst content, has been increasingly shown to improve the preoperative diagnosis in the majority of patients with undetermined PCs. The overall accuracy rates of EUS in differentiating neoplastic versus non-neoplastic lesions range from 40–93%, so EUS imaging features alone for PCs seem insufficient to make a diagnosis [3].

The 2006 Sendai Consensus Guidelines (SCG) [4] and the revised Fukuoka Consensus Guidelines (FCG) in 2012 established that patients with presumed but not proven mucinous cystic neoplasm should undergo surgical resection when high-risk stigmata are present [5]. However, these recommendations were established for mucinous cystic neoplasm and not for all PCs [6].

Other guidelines were suggested by the American College of Gastroenterologist (ACG) in 2007 [7] and more recently, in 2013, the European Expert Consensus (EEC) [8] stated that unless major contraindications were present, surgical resection should be considered in all symptomatic patients and in patients with MCN and MD/MT-IPMN with HRS or with evidence of some defined “worrisome features”. Recently, the American Gastroenterological Association (AGA) revised their previous guidelines, which were labelled as evidence-based rather than consensus-based [9]. However some investigators have expressed concern over whether adopting the AGA guidelines will result in low accuracy in identifying advanced neoplasia [10, 11].

Although outcomes after pancreatic surgery have improved over the last decades, this type of surgery still remains complex, with high morbidity and mortality ranging from 2–15% [12]. In contrast to ductal adenocarcinoma, cystic neoplasms with malignant potential are slow-growing, and a more favourable prognosis has been reported for these neoplasms, even in the setting of malignant degeneration [13].

Efforts to effectively and correctly identify those patients who might benefit from surgery and to identify other patients who would benefit from surveillance without therapy lack evidence by survival comparisons for the different classes of risk. We hypothesize that the EUS-FNA will yield high positive and high negative predictive values when applied to unselected consecutive patients affected by PCs with a minimum diameter ≥ 2 cm. The primary aim of this study was to critically evaluate the clinical utility and accuracy of the EUS-FNA in association with the SCG in malignant risk prediction of all PCs. The secondary aim of this study was to evaluate the natural course of all patients with PCs describing the outcome of different cohorts of patients and their long-term survival when they were stratified for the presence of benign or malignant PCs, and when they were submitted to surgical treatment or to clinical surveillance without treatment.

MATERIALS AND METHODS

Patients

From January 2007 to October 2015, 218 consecutive patients with undetermined PCs were admitted at Niguarda Hospital in Milan. Patients with a reported cytological or histological diagnosis referred to our Institution from other centers were excluded. Seventy-four patients presenting with a PC ≥ 2 cm with undetermined diagnosis and with initial radiological features of suspected mucinous cysts were eligible and included in the study receiving full clinical evaluation following SCG and EUS-FNA. Informed consent was obtained from all patients before performance of EUS-FNA according to the protocol approved by our Institutional Review Board and by the Regional Ethics Committee.

Patients with PCs smaller < 2 cm were excluded from the study and underwent a six months based follow up. A prospective database with all clinical and radiological data was first created in 2007 according the SCG. Furthermore all morphological, biochemical and cytological findings available with EUS-FNA were also recorded in the same database. At the end of the study all clinical and pathological features of the 74 patients were retrospectively reviewed by a multidisciplinary team.

Stratification of malignant risk according to SCG

Malignant risk was evaluated using radiological evaluation by US, CT-Scan, Magnetic resonance imaging...
(MRI) or magnetic Resonance Cholangiopancreatography (MRCP) and all relevant clinical findings. Patients were stratified into two classes of risk: high risk (HR) and low risk (LR) patients according to the SCG. According to the SCG, all patients with PCs showing high risk stigmata were considered at HR for malignancy if they had symptoms attributable to the cyst, if the cyst size was >3 cm irrespective of symptoms, or if the cysts were <3 cm in size with suspicious features such as the presence of symptoms, solid components like mural nodules and/or a dilated main pancreatic duct >6 mm. All PCs that did not meet these criteria for high risk stigmata were classified as LR.

**Stratification of malignant risk and the EUS-FNA procedure**

After evaluation with SCG all patient underwent EUS-FNA by a gastroenterologist of the Interventional Endoscopy Service who was blind to the previous evaluation. In all patients a new evaluation was obtained by adding EUS-FNA imaging information (size, location, septations, mural nodules, mass component, main duct communication, boards, and invasiveness) to the previous clinical and radiological work up. The cyst fluid content was evaluated for cytological analysis and for chemical and physical characteristics. Intraliesional CEA level were determined only when sufficient cyst fluid was obtained in order to better differentiate mucinous from non-mucinous cysts with the usual cut-off value of 192 ng/ml suggested by some Authors (2-9).

According to Pitman’s criteria [14] cytology was graded as: stage I-II-III-IV: non-diagnostic, atypical, negative for malignant and neoplastic benign; stage V, suspicious for malignancy; stage VI, positive for malignancy.

Based on these findings, only patients with cytology at stage V and VI were considered at HR and were considered possible candidates for curative surgery. When none of these criteria were present (stage I, II, III, IV) patients were considered at LR and submitted to a 3-6 months interval of surveillance depending on the cyst size and on the clinical course.

Patients with SCG considered at HR but with adequate cytology negative for malignant cells were considered at LR and received 3-months-based follow up. The technique of EUS-FNA has been previously described in detail [15]. The fine needle biopsy procedure was repeated until sufficient material was aspirated. The needles normally used were the same as those for solid lesions, 19 and 22 gauge.

**Definitive diagnosis**

In all patients the definitive diagnosis was obtained by cytological examination and or surgical specimen. The 30 items of the STARD 2015 (Standards for Reporting of Diagnostic Accuracy Studies Statements) were observed as guiding principles [16]. For all patients a definitive diagnosis of malignant or of benign PC was reviewed at the end of follow-up by a multidisciplinary team composed by a cytohistopathologist, surgeon, and gastroenterologist and it was strictly based on the histological specimen in all patients submitted to surgery or on cytological criteria obtained by EUS-FNA in other patients.

**Classification of PCs**

According to the WHO classification [17] all lesions were classified as follows: mucinous neoplasm (MCN), serum cyst adenoma (SCA), main-duct/mixed type intraductal papillary mucinous neoplasm (MD/MT-IPMN), branched-duct intraductal papillary mucinous neoplasm (BD-IPMN), pancreatic pseudocysts (PPC), pancreatic neuroendocrine neoplasm (PNEN), solid pseudopapillary neoplasm (SPN), and pancreatic duct adenocarcinoma (PDAC). As suggested by the Japanese Pancreas Society, the latter group was subdivided into IPMN-derived pancreatic duct adenocarcinoma (IPMN-DPAC) and IPMN-concomitant pancreatic duct adenocarcinoma (IPMN-CPDAC) [18].

**Indication for surgery**

Our recommendation was to resect PCs in those patients at HR for malignancy after EUS-FNA evaluation provided that patients were considered good surgical candidates with a reasonable life expectancy. Despite some patients were considered at LR surgery was considered in those patients with major symptoms suffering from recurrent abdominal pain or back pain unrelated to other causes, or in the presence of recurrent pancreatitis, worsening diabetes, jaundice and weight loss or gastro-duodenal outlet obstruction due to extrinsic compression by the PC. All other patients with PCs who did not meet these criteria or classified at LR underwent clinical surveillance.

**Outcome evaluation and statistical analyses**

Accuracy, sensitivity, specificity, negative and positive predictive value of combined SCG and EUS-FNA evaluation were calculated by using standard 2x2 contingency tables; the definitive histological or cytological diagnosis (reference standard) was considered to classify all PCs as malignant or benign lesion; detection of HR (possible malignant neoplasm) or LR (possible benign neoplasm) at the time of provisional diagnosis was obtained after the combined two steps evaluation with SCG associated to EUS-FNA. The overall survival curve was calculated for the group of 74 patients and was calculated from the time of first EUS-FNA. A Kaplan-Meier survival analysis comparison was performed for the cohort of patients who underwent surgery and for the cohort of patients who underwent clinical surveillance. Statistical analysis by survival comparison was obtained between two cohorts of patients with benign and malignant PCs. Differences in survival curves were compared by log-rank testing (Mantel-Cox). Statistical significance was determined at P < 0.05.
RESULTS

Seventy-four patients presented with 38 PCs in the head, 24 in the body and 12 in the tail of the pancreas. Nine patients of 74, originally excluded from the study with a small PC (< 2 cm) showed progression of the PC diameter during the follow up and were subsequently included in the study. No major complications were registered after the EUS-FNA procedure. According to Common Terminology Criteria for Adverse Events (CTCAE) 4 patients had mild early complications: 2 patients presented fever and 2 mild pancreatitis (amylase increased to at least three times the normal values in addition to abdominal pain); one patient had moderate grade 1 complication (intracystic bleeding after complete fluid evacuation). All complications resolved with medical therapy, within 3 days.

Twenty-five patients underwent surgery and histology was obtained from surgical specimen or by surgical biopsy of the lesion. EUS-FNA cytology was diagnostic in 69 of 74 patients. Sufficient fluid for intracystic CEA determination was available only in 31 patients (40%) and was not considered in our analysis. Two patients of 74 with radiological progression of disease who had nondiagnostic cytology, were submitted to a second attempt by EUS-FNA: both patients underwent surgery and only in one patient a malignant cytology could be evidenced.

Table 1 summarizes the distribution of different types of PCs for the 74 patients (MCN, SCA, MD/MT-IPMN, BD-IPMN, PPC, IPMN-DPDAC, IPMN-CPDAC and PNEN) according to age, sex and presence of high-risk stigmata evaluated by SCG/EUS-FNA, number of diagnostic cytological diagnoses available, and diameter of the lesions.

Accuracy, positive and negative predictive value

In Table 2 are reported accuracy, sensitivity, specificity, positive and negative predictive value obtained with SCG and EUS-FNA evaluation in detecting malignant PCs when histological or cytological diagnosis is taken as the reference standard.

Malignant PCs

In 14 patients (18.9%), a malignant tumour was diagnosed (10 pancreatic ductal adenocarcinoma and 4 neuroendocrine tumours). Ten of 14 patients with malignancy were considered clinically fit and were submitted to surgical treatment; four patients deemed unfit for surgery were followed up by oncologists and gastroenterologists with the best available medical treatment.

Table 1: Definitive diagnosis of PCs in 74 patients according to age, sex, presence of high risk stigmata (HRS) according to SCG, diagnostic versus non-diagnostic cytology, diameter of the lesions. The distribution of definitive diagnoses is expressed in decreasing order for different PC frequencies.

<table>
<thead>
<tr>
<th>Definitive diagnosis</th>
<th>N. Patients (%)</th>
<th>Age (range)</th>
<th>Sex M/F</th>
<th>HRS according to SCG/EUS-FNA</th>
<th>Diagnostic Cytology with EUS-FNA</th>
<th>Diameter (mean value in mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCA</td>
<td>20 (27)</td>
<td>27–89</td>
<td>11/9</td>
<td>0</td>
<td>18</td>
<td>37.6 ± 13.3</td>
</tr>
<tr>
<td>PPC</td>
<td>17 (22)</td>
<td>34–78</td>
<td>13/4</td>
<td>0</td>
<td>17</td>
<td>101 ± 50.9</td>
</tr>
<tr>
<td>MCN</td>
<td>15 (20)</td>
<td>44–79</td>
<td>8/7</td>
<td>4</td>
<td>14</td>
<td>33.7 ± 12.1</td>
</tr>
<tr>
<td>IPMN-DPDAC</td>
<td>8 (10.8)</td>
<td>48–82</td>
<td>5/3</td>
<td>5</td>
<td>7</td>
<td>53.6 ± 19.3</td>
</tr>
<tr>
<td>MD/MT-IPMN</td>
<td>4 (5.4)</td>
<td>59–83</td>
<td>2/2</td>
<td>1</td>
<td>4</td>
<td>25.7 ± 3.1</td>
</tr>
<tr>
<td>BD-IPMN</td>
<td>4 (5.4)</td>
<td>48–87</td>
<td>1/3</td>
<td>0</td>
<td>3</td>
<td>23.2 ± 0.31</td>
</tr>
<tr>
<td>PNEN</td>
<td>4 (5.4)</td>
<td>44–68</td>
<td>2/2</td>
<td>4</td>
<td>4</td>
<td>33.3 ± 12.1</td>
</tr>
<tr>
<td>IPMN-CPDAC</td>
<td>2 (2.7)</td>
<td>66–69</td>
<td>1/1</td>
<td>1</td>
<td>2</td>
<td>38±5.11.0</td>
</tr>
<tr>
<td>Overall</td>
<td>74</td>
<td>27–89</td>
<td>43/31</td>
<td>15</td>
<td>69</td>
<td>49.5±24.5</td>
</tr>
</tbody>
</table>

Abbreviations: SCA Serous Cystadenoma; PPC Pancreatic Pseudocyst, MCN Mucinous Cystic Neoplasm, MD/MT-IPMN Main Duct or/and Mixed Type-Intraductal Papillary Mucinous Neoplasm, BD-IPMN Branched Duct-Intraductal Papillary Mucinous Neoplasm, IPMN-DPDAC IPMN-Derived Pancreatic Duct Adenocarcinoma, IPMN-CPDAC IPMN-Concomitant Pancreatic Duct Adenocarcinoma, PNEN Pancreatic Neuroendocrine Neoplasm
Surgical treatment

A total of 25 of 74 patients underwent surgery. Major surgical resections with curative intent (6 pancreaticoduodenectomy and 4 distal pancreatectomy) were performed in 10 patients evaluated at high risk for malignant lesions (5 IPMN-DPDAC, 2 IPMN-CPDAC and 3 PNEN). Fifteen patients with symptomatic benign PCs (8 PPC, 4 MCN, 2 with SCA, 1 with MD/MT-IPMN) were submitted to pseudocyst-jejunostomy, pseudocyst-gastrostomy, distal pancreatectomy or atypical pancreatectomy.

Survival

At the end of follow-up, 62 of 74 patients are alive with a mean follow-up for all patients of 46.7 months. The overall survival rate for all patients was 93% at 1 year, 85% at 3 years, and 80% at 5 years (Figure 1). The survival rate for patients with benign PCs, with the neuroendocrine tumours and with malignant ductal adenocarcinoma was respectively 94%, 100% and 85% at 1 year, 90%, 100% and 41% at 3 years and 85%, 70% and 41% at 5 years; the difference in survival rate for patients with benign or neuroendocrine tumours when compared with that of patients with malignant ductal adenocarcinoma was statistically significant (P < 0.005 by log-rank testing, Fig 2). The survival rate of patients who underwent observational follow-up or surgical procedures was, respectively, 93% and 93% at 1 year, 90% and 80% at 3 years, 85% and 70% at 5 years (N.S. P > 1 by log-rank testing, Figure 3).

DISCUSSION

PCs represent a wide collection of tumours with different malignant potential at clinical presentation, and the correct choice between surgical excision and follow-up without therapy is a challenging topic of debate. The majority of patients discovered to have a PC is completely asymptomatic and the estimated prevalence in the general population is around 3.5% [19].

Several diagnostic modalities involving cross-sectional radiological imaging or endoscopy are useful for narrowing down the diagnosis and can give evidence to propose surgery or surveillance [20, 21]. However, a definitive diagnosis is often difficult without supporting cytological or histological evidence by means of EUS-FNA or surgical resection. The majority of the guidelines and recommendations proposed during last ten years [4–7] were designed specifically for the management of MCNs and IPMNs, and the major assumption was that all patients with MD/MT-IPMNs and MCNs with so called “high risk stigmata” according to SCG in 2006 (or
“worrisome features” according to FCG in 2012) should be considered for resection, whereas patients with selected non-malignant BD-IPMNs could be observed. However, a preoperative diagnosis of a MCN or IPMN is frequently unavailable, especially via cross-sectional imaging features alone. For that reason, the clinical application of these guidelines remains limited, especially in the initial triage of those patients who present with an incidental PC, due to the difficulty in distinguishing not only between MCNs and IPMNs but also between mucinous PCs and other PCs, such as SCA, PPC, and PNEN [22, 23].

The first aim of our study was to investigate the potential malignant risk of all undetermined PCs with a diameter ≥ 2 cm during an nine-year period with EUS-FNA in association with the conventional clinical and radiological work up proposed by SCG in 2006. The choice to limit our study to patients with PCs with a cut-off diameter of ≥ 2 cm, although arbitrary, was suggested by the very low yield of FNA for cysts < 1.5 cm and by the reported lower risk of malignancy for small cysts [24]. When international clinical guidelines are utilized (SCG, FCG, ACG, AGA, EEC) different results have been also reported with lower positive predictive values ranging from 29–66%, [25]. These findings may suggest that if international guidelines were applied during the early triage of patients with PCs, in one out of three patients potentially submitted to surgical resection, no malignancy can be found despite the fact that the hazard ratio of pancreatic cancer risk in those patients has been evaluated to be significantly higher when compared with the rest of patients without cysts [26]. In our study we registered only one false positive malignant risk evaluation in one symptomatic patient who was submitted to surgery for jaundice and gastric outlet obstruction.

The second aim of our study was to follow up and verify the outcome of all patients with benign and malignant disease as well as the outcome of patients who underwent surgical treatment during the 9-year study period. A considerable overall survival rate for the 14 patients with malignant PCs was observed (41% at fifth year for 10 patients with ductal adenocarcinoma and 70% at fifth year for four patients with neuroendocrine tumours). The survival rate of patients with ductal adenocarcinoma was 41%. This was statistically inferior to that observed in patients with benign PCs (85% at fifth year). However, the observation of a 41% survival rate for patients with ductal adenocarcinoma might support the fact that the natural course of the malignant pancreatic cysts seems more favourable when compared to that of other form of non cystic presentation of pancreatic adenocarcinoma, in which usually less than 30–40% of patients usually survive after five years [27]. Major technical controversies exist concerning the diagnostic yield of EUS. These lie in the fact that it is virtually impossible to acquire adequate fluid for the examination of cysts less of than 15 mm, and it is impossible to aspirate fluid from, on average, half of the cysts, either because the solid component predominates (as in the case of microcystic SCA) or because the IPMN has a highly viscous content [28]. The use of a 19 and 22-gauge needle was associated with a low rate of complications (6.75%) in accord with other clinical reports [29] and enabled us to obtain adequate diagnostic cytological material in 69 patients of 74 (93%); in the remaining patients the histological surgical specimen was available.

A PNEN was found in 4 patients (5.4%); this finding is similar to that reported in the literature (8%) and seems to be clinically relevant, considering that PNENs are relatively rare lesions and that most of these tumors are clinically non-functioning [30]. PNEN is a hypoechogenic tumor with overt vascularity. Sometimes, this hypoechogenic image can be confused with an anechoic cyst. However, the vascularization of the septa in a cyst might be confounding. In the case of cystic degeneration of a PNEN, the differential diagnosis should always require the support of EUS-FNA.

**CONCLUSION**

Despite some limitations due to the retrospective nature and to the small sample of patients, our study seems to support the clinical utility of the endoscopic-ultrasound-fine-needle aspiration (EUS-FNA) as a valid diagnostic tool in association to Sendai Consensus Guidelines (SCG) evaluation. Combining clinical evaluation by SCG and endoscopic, morphological and cytological information by EUS-FNA a high accuracy, high positive and high negative predictive value are
obtained which allows appropriate selection of patients with suspected malignant PCs who can benefit for surgery avoiding unnecessary, high-risk surgical procedures for many other patients. EUS-FNA associated to SCG can be recommended during the early diagnostic stage of patients with pancreatic cysts ≥ 2 cm allowing appropriate selection of those patients with a high malignant risk for surgical treatment with satisfactory long term survival. Further prospective multicenter studies could better evaluate the real advantage of EUS-FNA with other different proposed clinical guidelines.

********

Author Contributions

Pietro Gambitta – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Paolo Aseni – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Paola Fontana – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Emilia Bareggi – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Edoardo Forti – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Alberto Tringali – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Francesco Molteni – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Maurizio Vertemati – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor

The corresponding author is the guarantor of submission.

Conflict of Interest

Authors declare no conflict of interest.

Copyright

© 2016 Pietro Gambitta et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES


